tianjin dev (00882): tianjin lisheng pharmaceutical's net income attributable to parent company for the first three quarters was 0.169 billion yuan

Tianjin dev (00882) announced that its indirectly non-wholly-owned subsidiary tianjin lisheng pharmaceutical has until September 3, 2024...

Zhitong FinanceOct 29 18:12 ET

Express News | Tianjin Development - 9-Mth Net Profit Attributable RMB169.3 Mln for Tianjin Lisheng Pharmaceutical

ReutersOct 29 18:04 ET

TIANJIN DEV: Unaudited Financial Results for the nine months ended 30 September 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.

HKEXOct 29 18:02 ET · Announcements

Tianjin Lisheng Invests 210 Million Yuan in China Bohai Bank's Structured Deposit

MT NewswiresSep 27 05:38 ET

tianjin dev (00882.HK) subsidiary subscribed 0.21 billion yuan to another structured deposit.

Gelonghui September 26th, Tianjin Development (00882.HK) announced that due to the expiration of the previous structured deposits, on September 26, 2024, the company's indirectly non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed a third CBHB wealth management agreement, subscribing to another structured deposit with a principal amount of 0.21 billion yuan.

Gelonghui FinanceSep 26 08:14 ET

Express News | Tianjin Development - Subscription of Wealth Management Product

ReutersSep 26 08:12 ET